Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased ...

Q2 2025 Management View CEO Todd Davis stated that "our new strategy at Ligand is working and producing tangible outcomes. Our second quarter results reflect strong momentum across our expanding ...

As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

Ligand expects full-year earnings in the range of $6.70 to $7 per share, with revenue in the range of $200 million to $225 million. This story was generated by Automated Insights ( ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Contacts Ligand Pharmaceuticals Incorporated Simon Latimer [email protected] (858) 550-7766 Twitter: @Ligand_LGND LHA Investor Relations Bruce Voss [email protected] (310) 691-7100 ...

Ligand Pharmaceuticals announced that its partner, Pelthos Therapeutics, has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum ...